![]() |
市場調查報告書
商品編碼
1342081
全球藥物發現人工智能市場預測(~2030 年)Artificial Intelligence in Drug Discovery Market Research Report Forecast to 2030 |
預計在預測期內,全球人工智能藥物發現市場規模將以 29.83% 的複合年增長率大幅增長。 人們對人工智能在藥物發現方面的接受程度不斷提高、人工智能在藥物發現方面重大舉措的興起以及利用人工智能的新藥物發現公司的激增正在推動商業領域的發展。
區域考慮
2022年北美市場佔據最大份額。
歐洲市場佔據第二大份額。
預計 2023 年至 2030 年亞太市場將出現顯著增長。
由於慢性病和傳染病的流行,藥品需求增加,中東/非洲/拉丁美洲市場可能會發展。
本報告研究和分析了全球人工智能藥物發現市場,提供市場動態、區域和細分分析、公司概況等。
The Artificial Intelligence in Drug Discovery Market is anticipated to register a substantial CAGR of 29.83% during the forecast period. The increasing reception of simulated intelligence in drug discovery, rising key initiatives for man-made intelligence in drug discovery, and the increasing number of man-made intelligence-powered drug discovery new companies are driving business sector development.
The reception of simulated intelligence in drug discovery is rising among industries, including drug and biotechnology organizations. This is essentially owing to the way that artificial intelligence offers progressed benefits to discovering drug particles and paces up the drug discovery process. Further, artificial intelligence gives significant insights to work on the designing, optimizing, and synthesizing of drugs. There are a few factors that are increasing the reception of man-made intelligence for drug discovery. The absolute most predominant ones include the rising incidences of ongoing illnesses and accuracy medicine, owing to the emerging way to deal with the counteraction and treatment of sicknesses. Besides, a few market members are increasing the accuracy of their drug portfolios, a cycle that has been seen to exhibit an increase in the reception of man-made intelligence advancements.
Based on product and service Artificial Intelligence in Drug Discovery, is classified into software and services. Based on a molecule type the market is divided into large molecules and small molecules. The Market of Artificial Intelligence in Drug Discovery based on technology is divided into machine learning, deep learning, and others.
Based on an indication the market is classified into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others. Based on an application the market is categorized into target identification, candidate screening, de novo drug designing, drug optimization and repurposing, and preclinical testing.
Regional Insights
The North American artificial intelligence in the drug discovery market represented the biggest piece of the pie in 2022. This is because of the increasing incidences of ongoing illnesses, many leading new companies, and increasing drug Research and development investments in the region.
Europe's artificial intelligence in the drug discovery market represents the second-biggest piece of the pie because of the rising pervasiveness of uncommon illnesses across Europe and increasing the demand for a simulated intelligence-driven stage for drug discovery. Moreover, Germany's market of artificial intelligence
The Asia-Pacific artificial intelligence in drug discovery market is supposed to develop at a huge offer from 2023 to 2030. This is because of the rising weight of sickness and the tremendous number of biopharmaceutical industries that are adopting computer-based intelligence abilities in the Asia-Pacific region.
The rest of the World is fragmented into the Center East, Africa, and Latin America. Artificial intelligence in the drug discovery market in the previously mentioned regions is probably going to observe development because of the increasing demand for drugs because of the rising incidences of persistent and infectious illnesses.
Key Companies in the Artificial Intelligence in Drug Discovery Market include IBM (US), Alphabet Inc (US), Atomwise Inc (US), Deep Genomics (Canada), Cloud Pharmaceuticals, Inc (US), Microsoft corporation (US), Insilico Medicine (China), Cyclica (Canada), BenevolentAI (UK), and Exscientia (UK).
TABLE OF CONTENTS